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Abstract
Microtubule inhibitor–induced Bcl2 phosphorylation is
detrimental to its antiapoptotic function. Phosphoryla-
tion of Bcl2 predominantly occurs on two serine
residues (70 and 87) in cells arrested at G2-M phase
by microtubule disarraying agents. Phospho Bcl2 can
associate with a cis–trans peptidyl prolyl isomerase,
Pin1. Pin1 and its homologues are known to target the
proline residue carboxyl terminal to the phosphorylated
threonine or serine residue of mitotic phosphoproteins,
such as Bcl2. However, it was not clear how an
extranuclear protein could associate with nuclear Pin1.
The confocal images of the immunofluorescence stud-
ies employing phospho Bcl2–specific antibody devel-
oped in the laboratory demonstrated the translocation
of phospho Bcl2 inside the nucleus. Interestingly,
proteasomal degradation of Pin1 facilitates dephos-
phorylation of phospho Bcl2 due to longer exposure of
Taxol. Here we show for the first time that proteasomal
degradation of Pin1 is the key factor to determine the
fate of phosphoforms of Bcl2. When Pin1 is degraded by
proteasomes, phospho Bcl2 is converted to its native
form. Thus, transient conformational change of Bcl2 due
to association with peptidyl prolyl isomerase can
contribute to irreversible apoptotic signaling.
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Introduction
Apoptosis is an intrinsic cell death program necessary for
development and tissue homeostasis within all multicellular
organisms [1-4]. The induction of the cell death program
can be helpful for evading the potential malignant outcome
of genomic damage. On the contrary, the deregulated
expression of a family of antiapoptotic oncogenes such as
Bcl2 can be a substantial factor for the development of
human malignancies [5,6 ]. The family of these oncoproteins
is comprised of both pro- and antiapoptotic members and
their ratio critically determines the apoptotic threshold
[1,2,7].
In recent years, studies on the posttranslational modifica-
tions of these proteins have revealed some interesting facts.
In the presence of survival factor IL-3, a proapoptotic protein,
BAD loses its biologic function by phosphorylation on two
different serine residues [8]. The pioneer of this family, the
antiapoptotic member Bcl2, is phosphorylated and is inacti-
vated by microtubule disarraying agents or in the presence of
phosphatase inhibitors [9-24]. The ASK1/Jun N-Terminal
protein kinase pathway phosphorylates Bcl2 during cell cycle
progression as a normal physiologic process to inactivate
Bcl2 at G2-M phase [10,11,13,15,20].
Intracellular signal transduction pathways play a crucial
role in a variety of cellular processes such as differentiation,
proliferation, or apoptosis, and the reversible phosphorylation
of their components is a major regulatory mechanism used to
control their activities. Bcl2, a 26-kDa integral membrane
oncoprotein contains a membrane-anchoring domain near
its carboxyl terminus that causes its insertion into intracellular
membranes of mitochondria and other organelles such as ER
[25-27]. Microtubule-damaging drug- induced phosphoryla-
tion of Bcl2 at G2-M phase predominantly occurs on two
serine residues: serine 70 and 87 and possibly to a small
extent on threonine 69. All of these phosphorylation sites
have a consensus motif consisting of serine/ threonine
residue followed by proline. Phospho Bcl2 can associate
with a cis–trans peptidyl prolyl isomerase Pin1 [28]. Pin1 and
its homologues [29-31] can target the proline residue
carboxyl terminal to the phosphorylated threonine or serine
residue of mitotic phosphoproteins. However, it was not clear
why and how an extranuclear protein like Bcl2 could
associate with nuclear Pin1.
Here we show that phospho Bcl2 is translocated inside the
nucleus and that its association with Pin1 can facilitate
dephosphorylation of phospho Bcl2 in a proteasome-
dependent manner [32-34]. Apparently, the association of
Pin1 with phospho Bcl2 can modulate its antiapoptotic
function by inducing a transient conformational change.
Subsequent proteasomal degradation of Pin1 destabilizes
Pin1/P-Bcl2 association, which may result in the enhanced
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access of phosphatase for phospho Bcl2, thereby converting
it to its native form.
Materials and Methods
Reagents
Mouse monoclonal antibodies against Bcl2 and PARP
were available fromUpstateBiotechnology (LakePlacid, NY)
and Pharmingen (San Diego, CA), respectively. Proteasome
inhibitors MG132, lactacystin, or PSI were purchased from
Calbiochem (San Diego, CA). Taxol was obtained from
SigmaChemical (St. Louis, MO). ECL detection reagent was
the product of Amersham Life Sciences (Piscataway, NJ). All
other reagents were of molecular biology grade. Polyclonal
antibody against Pin1 was obtained from Oncogene
Research Products (Cambridge, MA).
Cells and Culture Conditions
Human prostate cancer cells PC-3 were maintained in
minimum essential medium (MEM) supplemented with 10%
FBS and 50 g/ml gentamicin. Pre B leukemic cells 697
were grown in RPMI supplemented with 10% FBS and 50
g/ml gentamicin.
Stable transfection of wild- type Bcl2 Wild- type Bcl2 cDNA
cloned into pcDNA3 was stably transfected in PC-3 cells
using calcium phosphate coprecipitation method as des-
cribed before [35,36]. Cells were allowed to grow for
48 hours for the expression of the resistance gene.
Subsequently, cells were propagated in selective medium
containing 1 mg/ml geneticin until clones appear. The
positive clones were identified by immunoblot using mono-
clonal antibody against human Bcl2. Among the selected
clones, W-34 cells that overexpressed Bcl2 protein several
fold excess compared to the parental PC-3 cells were used
for further investigation.
Assessment of Bcl2 Phosphorylation or Pin1 Level
Cells were treated with specified concentrations of Taxol
or proteasome inhibitors ( freshly prepared) for varying
periods of time in a 5% CO2 incubator. Equal amounts of
protein extracted from cells were subjected to SDS-PAGE
followed by electrophoretic transfer onto nitrocellulose
Figure 1. Phospho Bcl2 is dephosphorylated due to longer exposure of Taxol. PC -3 (panel A ) or W-34 (panel B ) cells were challenged with 1 M Taxol for
indicated periods. Total protein extracts were immunoblotted using monoclonal antibody against Bcl2. The slower mobility forms of Bcl2 indicate phosphorylated
Bcl2. It is worth mentioning that whereas only 25 g protein was loaded in the case of W-34 cells, PC -3 cells required loading of 250 g protein to visualize the
phosphorylated form of Bcl2. Panel C: the extent of Taxol - induced apoptosis determined by DAPI staining of nuclei [ 23,26 ]. PC -3 cells treated with 1 M Taxol for
indicated periods were subjected to nuclear staining with DAPI (2 g /ml ). Approximately 150 cells were scored for each data point. All results are exhibited as
means±SD of three experiments. Panel D: PARP degradation by Western blot of Taxol - treated PC-3 cells [ 15,20 ]. Note that the intensity of 85 - kDa PARP
cleavage product increased with the longer period of exposure to Taxol.
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membranes. Transferred proteins on nitrocellulose mem-
branes were routinely visualized by Ponceau S staining to
check equal loading and further processed for immunoblot-
ting using monoclonal antibody against Bcl2 or rabbit
polyclonal antibody against Pin1. The phosphorylated forms
of Bcl2 protein were detected as slower migrating forms as
described previously [9-24]. The slower migrating forms of
Bcl2 were shown to be phosphorylated forms either by  -
phosphatase treatment or P32 labeling previously by others
and by our laboratory [9-24].
Assessment of Apoptosis
Apoptosis was determined by DAPI staining and PARP
cleavage. For DAPI staining, control and treated cells were
fixed and permeabilized with 0.5% Tween 20. The slides
containing the cells were mounted with a fluid containing
2 g/ml DAPI to stain nuclear DNA. A Nikon Eclipse E600
fluorescence microscope (Columbia, MD) was used for
fluorescence microscopy. For PARP degradation, the cells
were harvested following the scheduled exposure to the
designated concentration of paclitaxel. Equivalent amounts
of protein from each sample were electrophoresed on 5% to
15% gradient SDS-PAGE, transferred to membranes, and
followed by immunoblotting with monoclonal antibody
against PARP.
Cell Sorting by Flow Cytometry
Cells following designated drug treatment were stained
with Hoechst 33342 (Sigma) at a concentration of 15 g/ml
for 1 hour at 378C. 3,30 -Dipentyloxacarbocyanine iodide
(Molecular Probes, Eugene, OR) was added at a concen-
tration of 0.2 g/ml at the same time with Hoechst stain to
increase resolution of DNA distribution. Cells were sorted by
a fluorescence activated cell sorter at Ireland Cancer
Center’s core facility.
Development of Phospho Bcl2–Specific Antibody
Serine-70 residue of Bcl2 protein is the evolutionarily
conserved phosphorylation site [15]. To develop phospho
Bcl2–specific antibody the 15-mer Bcl2 peptide,
DPVARTS* PLQTPAAP (S* indicates phosphorylated ser-
ine-70 residue), was synthesized. HPLC-purified peptide
was coupled to KLH (Keyhole limpet hemocyanin) by the
glutaraldehyde method [37]. The peptide conjugate was
injected into rabbits to raise polyclonal antibody using
Freund’s adjuvant. Blood was collected before the first
injection to be used as preimmune sera. Following the third
injection, antibody titer was tested by Western blot. Serum
fractionated from whole blood of the immune animals was
used throughout these studies. The specificity of the
antibody was tested by blocking with preincubation of the
respective peptide.
Immunofluorescence Microscopy
Control and Taxol - treated cells were fixed in chilled
methanol /acetone (1:1) for 10 minutes at room temperature
and permeabilized with 0.5% Tween 20 in PBS for 5 minutes.
Permeabilized cells were blocked with 10% normal goat
serum (Vector Laboratories, Burlingame, CA) in PBS for
30 minutes at room temperature. Both groups of cells were
then incubated with 1:100 dilution of phosphospecific rabbit
Bcl2 polyclonal antiserum or mouse monoclonal Bcl2 anti-
body at room temperature for 2 hours. Following brief
washes with PBS containing 1% BSA and 0.1% Tween 20,
slides were incubated with fluorescein-conjugated goat
anti–rabbit IgG (Boehringer Mannheim, Indianapolis, IN)
Figure 2. Phospho Bcl2 and Pin1 decline at the same period of Taxol exposure and proteasome inhibitors can stabilize this decline. Panel A: Peptidyl prolyl
isomerase Pin1 is also down regulated at 48 hours exposure of Taxol and proteasome inhibitor MG132 can prevent this decline. W-34 cells were exposed to 1 M
Taxol in the presence or absence of proteasome inhibitor MG132 (20 M). Total protein extracts were subjected to Western blot using rabbit polyclonal antibody
against Pin1. Lane 1: Vehicle solvent for 24 hours; lane 2: 24 hours Taxol; lane 3: 48 hours Taxol; lanes 4 and 6: 48 hours Taxol and last 24 hours MG132; lane
5:24 hours MG132 alone. Panel B: Proteasome inhibitor MG132 can also stabilize the decline of phospho Bcl2 under identical conditions. Lane 1: Vehicle solvent for
16 hours; lane 2: 16 hours Taxol; lane 3: vehicle solvent for 24 hours; lane 4: 24 hours Taxol; lane 5: coincubation of MG132 and Taxol for 24 hours; lane 6: 24 hours
Taxol and last 16 hours MG132; lane 7: 24 hours vehicle solvent and last 16 hours MG132; lane 8: 24 hours vehicle solvent and MG132; lane 9: vehicle solvent for
48 hours; lane 10: 48 hours Taxol; lane 11: 48 hours Taxol and last 24 hours MG132; lane 12: 48 hours Taxol and last 16 hours MG132; lane 13: 48 hours vehicle
solvent and last 24 hours MG132; lane 14: 48 hours vehicle solvent and last 16 hours MG132.
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or CY3-conjugated anti–mouse IgG (Jackson Immunore-
search Laboratories, West Grove, PA) at a 1:200 dilution for
30 minutes at room temperature. Subsequently, slides were
washed and mounted with a fluid containing DAPI (Vector
Laboratories) to visualize the nuclear stain [23]. A Nikon
Eclipse E600 fluorescence microscope was used for fluo-
rescence microscopy. The computerized merged images
were taken using ‘‘SPOTRT’’ software program. For confocal
Figure 3. Phospho Bcl2 has shorter half - life ( t {1/2} ) than that of native Bcl2 and proteasome inhibitors can stabilize phospho Bcl2 even in the presence of
cycloheximide (CHX). Panels A and B: 16 -hour 1 M Taxol – treated W-34 cells were incubated with or without proteasome inhibitors ( 20 M MG132 /10 M
lactacystin ) in the presence or absence of CHX (20 g /ml ) for the indicated periods. Panel A: 16 -hour Taxol - treated cells were further incubated. Lane1: no CHX
(0 hours ); lanes 2 and 7: 2 hours without or with CHX treatment, respectively; lanes 3 and 8: 4 hours without or with CHX, respectively; lanes 4 and 9: coincubation
for 4 hours with either MG132 ( lane 4 ) or CHX and MG132 ( lane 9 ); lanes 5 and 10: 6 hours without or with CHX, respectively; lanes 6 and 11: coincubation for
6 hours with either MG132 ( lane 6 ) or CHX and MG132 ( lane 11 ). Panel B represents identical experiments except another proteasome inhibitor lactacystin was
used instead of MG132. Panel C: W-34 cells were incubated with or without 20 g /ml CHX for indicated time periods. Equal amounts of proteins were subjected to
immunoblotting using Bcl2 monoclonal antibody.
Figure 4. Phospho Bcl2 and Pin1 have similar half - life ( t {1/2} ). Panel A: 16 -hour 1 M Taxol– treated W-34 cells were incubated with CHX in the absence or
presence of proteasome inhibitor MG132. Cell lysates were subjected toWestern blot with Pin1 antibody. Lane1: control; lane 2: 16 -hour Taxol treatment; lanes 3, 4,
6: 16 hours Taxol followed by 2, 4, and 6 hours CHX treatment, respectively; lanes 5 and 7: 16 hours Taxol followed by coincubation with CHX and MG132 for 4 and
6 hours, respectively. Panel B: 16 - hour 1 M Taxol - treated W-34 cells were incubated with CHX in the absence or presence of other proteasome inhibitors
lactacystin /PSI for 6 hours. Lane 1: control; lane 2: 16 hours Taxol treatment; lane 3: 16 hours Taxol followed by 6 hours CHX treatment; lanes 4 and 6: 16 hours
Taxol followed by 6 hours coincubation with CHX and lactacystin; lanes 5 and 7: 16 hours Taxol followed by 6 hours coincubation with CHX and PSI.
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microscopy, 20 nM TO-PRO (Molecular Probes) was used
for nuclear staining. Images were captured on a Leica SP2
confocal microscope at the Institute’s core facility.
Results
Phospho Bcl2 Is Dephosphorylated due to Longer Exposure
of Taxol
Previous studies performed by us in regard to Bcl2
phosphorylation were limited to 16 to 24 hours exposure of
Taxol. Initially, we were interested in testing the effect of
Taxol on the phosphorylation status of Bcl2 for longer periods
of treatment. Parental PC-3 or W-34 cells (PC-3 ectopically
overexpressed with wild- type Bcl2) were challenged with
1 M Taxol for different time periods (8 to 72 hours). As
evident in Figure 1, A and B, the extent of Bcl2 phosphor-
ylation reaches a peak at 16 hours (Figure 1, A, lane 3and B,
lane 4 ) whereas longer periods of exposure of Taxol such as
48 or 72 hours lead to the decline of phosphoforms of Bcl2
(Figure 1, A, lanes 5 and 6 and B, lanes 8 and 10 ). Of note, in
endogenously low Bcl2-expressing PC-3 cells only one
phosphorylated form is detectable. However, when it is
ectopically overexpressed in the same cells (W-34 clone),
additional hyperphosphorylated forms of Bcl2 are evident
following the same period of Taxol exposure. Bcl2 gets
predominantly phosphorylated on Serine 70 residue follow-
ing treatment with microtubule damaging agents. Phosphor-
ylation on other weak sites is visible only when it is
overexpressed, as in the case of W-34 cells.
Bcl2 is phosphorylated by ASK1/Jun N-terminal protein
kinase pathway that is normally activated at G2-M phase of
the cell cycle [10]. However, the phospho Bcl2 cannot be
sustained in G2-M–arrested cells, but apoptosis continues
even if dephosphorylated native Bcl2 returns after longer
exposure of Taxol. As evident in Figure 1, C and D, 16-hour
exposure of Taxol to PC-3 cells can lead to significantly less
DNA fragmentation and PARP cleavage than that of 48-hour
exposure. Our data are in concordance with the previous
observation [38]. Apparently, dephosphorylation of Bcl2
cannot cause the reversion of cells from the executioner
stage of apoptosis.
Phospho Bcl2 and Pin1 Decline at the Same Period of Taxol
Exposure and Proteasome Inhibitors Can Stabilize This
Decline
Recent observation implicates the association of phospho
Bcl2 with Pin1 in M phase arrested cells [28]. Pin1- induced
cis–trans isomerization of the peptide bond at the amino side
of proline residue develops tangible structural changes in the
target protein [29-31]. These conformational changes could
alter protein stability or cellular architecture. We asked
whether the association of Pin1 is the key mechanism to
sustain phosphoforms of Bcl2. Thus, we were interested in
testing the status of Pin1 when phospho Bcl2 disappears.
The decline of Pin1 was evident following 48-hour Taxol
treatment (Figure 2A, lane 3 ). This event led us to think that
their concomitant decline might be interdependent. We
considered that perhaps the downregulation of Pin1 is
proteasome mediated [32-34]. Interestingly, cell permeable
proteasome inhibitor MG132 can prevent this decrease
of Pin1 in Taxol -arrested mitotic cells (Figure 2A, lanes 4
and 6 ). Similarly, the disappearance of phospho Bcl2 can be
blocked under conditions when proteasomes are not in the
activated state (Figure 2B ).
The data presented in Figure 2B clearly documents that
the gradual decline of phospho Bcl2 in prostate cancer
cells can be prevented in the presence of 20 M MG132
(Figure 2B, lanes 11and 12 ). Nevertheless, in all cases,
pretreatment of Taxol was always necessary before the
addition of MG132. Usually, 16 to 24 hours of Taxol
treatment leads to peak accumulation of phospho Bcl2, but
no accumulation of phospho Bcl2 was evident if MG132 is
added together (Figure 2B, lane 5 ). Some accumulation of
phospho Bcl2 is noted if MG132 is added after 8 hours of
Taxol treatment (Figure 2B, lane 6 ). As shown in Figure 2B
( lane 10 ), no or little accumulation of phosphoforms of Bcl2
is noted due to 48 hours of Taxol exposure. Interestingly, if
we add MG132 for the last 24 and 16 hours of the total 48-
hour incubation period with Taxol, phospho Bcl2 can be
stabilized to a different extent (Figure 2B, lanes 11 and 12 ).
Of note, incubation of MG132 during the last 24 hours can
accumulate more than that of 16 hours (Figure 2B, lane 11
vs. lane 12 ). The inability of Taxol to accumulate phospho-
forms of Bcl2 in the presence of MG132 can be explained if
MG132 can block cell growth at G1 phase. Because Taxol -
induced Bcl2 phosphorylation predominantly occurs at G2-
M phase of the cell cycle, MG132 - induced G1 arrest might
be a contributing factor to hinder Bcl2 phosphorylation. That
MG132 can arrest cells at G1 phase is reported in the
literature [39]. Because Pin1 is expressed in mitotic phase,
we also find diminished expression of Pin1 in cells treated
with MG132 only (Figure 2A, lane 5 ) for the same reason.
Phospho Bcl2 and Pin1 Have Similar Half -Lives ( t {1/2} ) and
Proteasome Inhibitors Can Restore Their Destabilization
To determine whether phosphorylated forms of Bcl2
disappear faster than the nonphospho form, Bcl2-over-
expressing PC-3 cells were first treated with 1 M Taxol for
16 hours. The levels of phospho Bcl2 were monitored in the
presence or absence of 20 g/ml cycloheximide for several
Figure 5. Taxol - induced G2 -M phase arrest is unaltered by posttreatment
with CHX. W-34 cells were either treated with ( i ) 1 M Taxol for 22 hours or
( ii ) 22 hours Taxol ( 1 M) with CHX (20 g /ml ) for the last 4.5 hours. Cell
cycle distribution was analyzed by flow cytometry.
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time periods (2 to 6 hours). Similar approaches using
cycloheximide were undertaken to determine the half - lives
( t {1/2} ) of other proteins such as p53 and survivin [40,41]. In
the presence of protein synthesis inhibitor, cycloheximide
(CHX), phospho Bcl2 starts to disappear significantly at
4 hours with almost complete decline after 6 hours addition of
CHX (Figure 3A, lanes 8 and 10 ). However, simultaneous
treatment with 20 M MG132 prevents this decline of
phospho Bcl2 (Figure 3A, lanes 9 and 11 ). Figure 3B
indicates a similar observation in the presence of another
Figure 6. Characterization of phospho Bcl2–specific antibody by Western blot and immunofluorescence microscopy. Panel A: Phospho Bcl2–specific antiserum
specifically recognizes phosphoforms of Bcl2 on Western blot. Lanes 1 and 3: Untreated W-34 cell lysate; lanes 2, 4, 5: Taxol - treated W-34 cell lysate. Panel B:
Immunofluorescence microscopy with phosphosBcl2–specific antiserum. Pre B cells 697 expressing endogenous Bcl2 as well as W-34 cells (Bcl2 - transfected
PC-3 ) were treated with DMSO or 1 MTaxol for 16 hours. Both control and treated cells were double labeled for DAPI and FITC. Note that merged images indicate
the presence of FITC - labeled phospho Bcl2 inside the nucleus in the case of Taxol treatment. Images shown are representative of typical cells most commonly
observed in these experiments.
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proteasome inhibitor, lactacystin. We also examined the
half - life of native Bcl2 by a similar approach. In the presence
of CHX (20 g/ml), native Bcl2 partially declines after 16 to
24 hours addition of CHX (Figure 3C ). Clearly, the half - life of
native Bcl2 is much longer than that of phospho Bcl2.
Additionally, the status of Pin1 was examined in the
presence of cycloheximide in Taxol - treated cells. Sixteen-
hour Taxol - treated cells were exposed to CHX for different
time periods (2 to 6 hours). Strikingly, from 4-hour CHX
treatment the level of Pin1 starts to decline (Figure 4A, lane
4 ) and the significant reduction of Pin1 was observed
following 6-hour CHX treatment (Figure 4A, lane 6 ). The
kinetics is identical to that of phospho Bcl2 decline. More
interestingly, coincubation with specific proteasome inhibitor,
MG132, results in the stabilization of Pin1 (Figure 4A, lanes
5 and 7 ). Not only MG132 but also other proteasome
inhibitors lactacystin and PSI behave in a similar fashion to
stabilize Pin1 (Figure 4B ). Notably, due to G2-M arrest
following initial Taxol exposure, the level of mitotic protein
Pin1 was increased (Figure 4, A and B, lane 2 ). Our data
strongly suggest that proteasome-mediated destabilization
of Pin1 plays a major role in the decline of phospho Bcl2.
Cycloheximide Treatment Does Not Alter G2-M Profile
Induced by Taxol
Because the protein synthesis inhibitor cycloheximide
(CHX) can arrest cells at G1 phase [42], it has been shown
that Taxol - induced Bcl2 phosphorylation can be blocked by
the pretreatment with this agent (Basu et al., unpublished
data). As shown in Figure 3, A and B, Taxol - induced
phosphoforms of Bcl2 gradually decline in the presence of
CHX. To assess whether such decline of phospho Bcl2 in the
presence of CHX is due to G1 phase arrest, the following
groups of cells were chosen: (a) Taxol treated for 22 hours;
(b) Taxol treated for 22 hours with CHX for the last 4.5 hours.
These groups of cells were sorted by flow cytometry into two
major populations: ( i ) G0-G1-S and ( ii ) G2-M. Interest-
ingly, Taxol - induced G2-M arrest remains unaffected if CHX
addition follows Taxol treatment (Figure 5). This indicates
that once the cells are in G2-M phase of the cell cycle, CHX
cannot revert them to G1 phase of growth arrest. Thus, the
disappearance of phospho Bcl2 as observed in Figure 3, A
and B, cannot be attributed to the ability of CHX to cause G1
phase arrest.
Phospho Bcl2 Is Translocated to the Nucleus
Because Bcl2 is exclusively localized in mitochondrial
membrane with trace amounts found in the ER and nuclear
membranes [25-27], we asked the question how phospho
Bcl2 interacts with a nuclear protein Pin1. One postulation
was that phospho Bcl2 is translocated from other organelles
to inside of the nucleus. For this purpose, a phospho Bcl2–
specific peptide antibody was developed. Initially, studies
were undertaken to characterize the specificity of this
antibody.
Nitrocellulose strips containing control and Taxol - treated
W-34 cell lysate were probed with preimmune rabbit serum
(Figure 6A, lanes 1 and 2 ), phospho Bcl2–specific anti-
serum (Figure 6A, lanes 3 and 4 ) as well as mouse mono-
clonal antibody against Bcl2 (Figure 6A, lane 5 ). Preimmune
rabbit serum did not react with any form of Bcl2 as evident
from Figure 6A ( lanes 1 and 2 ). Phospho Bcl2–specific
antibody specifically reacted with only two slower migrating
phosphoforms of Bcl2 (Figure 6A, lane 4 ). Preincubation of
the antiserum with the specific peptide used as immunogen
abolished this reaction (Basu et al., unpublished observa-
tion). Mouse monoclonal antibody used to probe lane 5 is
known to recognize both native and phosphoforms of Bcl2.
Thus, the phospho Bcl2–specific antibody specifically
recognizes phosphoforms of Bcl2 on Western blots.
Next, we were interested in determining whether this
antibody can specifically recognize phospho Bcl2 inside the
cells. For this purpose, two cell lines were chosen: (a) Pre B
leukemic cells 697, which endogenously express Bcl2, and
(b) W-34 cells (PC-3 cells genetically engineered to
overexpress Bcl2). Control and Taxol - treated cells were
subjected to immunofluorescence microscopy using phos-
pho Bcl2–specific antibody as primary. Phospho Bcl2 was
detected by using FITC-conjugated anti–rabbit IgG. FITC-
labeled phosphoforms of Bcl2 were clearly evident in only
Taxol - treated cells Figure 6B. Normally, native Bcl2 is
localized on the intracellular membranes, predominantly on
mitochondrial membrane [25-27]. To ascertain whether any
change in localization occurred following posttranslational
modification, we stained the cells with both FITC and a
nuclear-specific stain (DAPI). Our dual - labeling studies
clearly indicate that phospho Bcl2 is translocated inside the
nucleus (uppermost panels of Figure 6B ).
The above immunofluorescence data was confirmed by
confocal microscopy. Figure 7B represents the merging of
FITC- labeled phospho Bcl2 inside the nucleus as defined by
Figure 7. Confocal microscopy with phospho Bcl2–specific antibody. (A )
FITC - labeled single optical section. (B ) Differential interference contrast
images. (C ) Merged images of (A ) and (B ). (A, B, C ) Taxol - treated W-34
cells. Panel D indicates no FITC labeling of untreated W-34 cells.
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the single optical section of differential interference contrast
images (Figure 7C ).
The confocal images were also taken using mouse
monoclonal antibody that recognizes both phospho and
nonphospho forms of Bcl2. In untreated PC-3 cells, the
localization of Bcl2 is extranuclear as evident in Figure 8F
whereas Taxol treatment resulted in CY3 fluorescence
distribution inside the TO-PRO–stained nuclei. It was
interesting to note that phospho Bcl2 cannot specifically
enter the intact nuclei (Figure 8, C and E ). As noted in Figure
8, B and D, the intranuclear localization of phospho Bcl2 is
evident only in the cells with destabilized nuclear envelope. It
is known that Taxol can induce mitotic arrest and during
mitosis, nuclear envelope breakdown occurs shortly after the
centrosome separation [28]. Undoubtedly, the single optical
sections obtained by confocal microscopy enabled us to
resolve the puzzle how phospho Bcl2 can associate with
nuclear Pin1.
Discussion
Microtubule disarraying agents can trigger cell death follow-
ing G2-M arrest [43-47]. Previous studies have demon-
strated that Bcl2 is normally phosphorylated during mitosis
[10,48]. Our flow cytometry studies with wild - type and S70, 87
A (phosphorylation defective mutant) Bcl2 transfected cells
exhibited similar extent of mitotic arrest (Basu et al.,
unpublished observation). Thus, Taxol -mediated Bcl2 phos-
phorylation is the consequence of prolonged G2-M arrest
due to drug exposure. But the phosphorylation defective
mutant of Bcl2 exhibited enhanced antiapoptotic activity in
comparison with the wild- type counterpart [10,13]. The
ASK1/JNK1 pathway is activated at G2-M phase of the cell
cycle to inactivate the antiapoptotic protein Bcl2 [10,13].
PKC, however, has been implicated in the phosphorylation
of Bcl2 on serine 70 following IL-3 treatment of hemato-
poietic cells [49]. Whereas Ito et al. [49] observed that the
S70A mutant of Bcl2 can exert less antiapoptotic function in
the IL-3–dependent cell line NSF/N1.H7, Yamamoto et al.
[10] noted enhanced antiapoptotic effect of the same mutant
in another IL-3–dependent cell line, FL5.12. Interestingly, in
contrary to PKC, another isoform of protein kinase C, PKC
delta, can translocate to mitochondria to trigger apoptosis
[50].
Ling et al. [38] observed that Bcl2 phosphorylation
reaches a peak after 24 hours Taxol treatment and phospho-
forms gradually disappear to be converted to dephosphory-
lated or native Bcl2. Our results are in agreement with these
studies. However, the mechanism of regulation of phosphor-
ylation–dephosphorylation was not clear. Very recent
observation describing the specific association of a mitosis
specific nuclear protein Pin1 with phospho Bcl2 was also
puzzling to us. We thought about one possibility, that
following Taxol treatment phospho Bcl2 is being translocated
inside the nucleus. Indeed, phospho Bcl2–specific antibody
could recognize Bcl2 inside the nucleus of Taxol - treated
cells (Figure 6B ). To our knowledge, this is the very first
report of translocation of phospho Bcl2 into the nucleus
employing such unique reagent. Bcl2 does not contain
typical nuclear localization signal (NLS) sequences. The
most plausible mechanism of translocation seems to be
passage through the dissolved nuclear envelope during
mitosis as discussed earlier [28].
Another novel finding of our studies is the proteasomal
degradation of Pin1, a member of the peptidyl prolyl
isomerase family. The sequence-specific and phosphoryla-
tion-dependent proline isomerization by Pin1 is well estab-
lished [51-54]. Prolyl isomerases catalyze relatively slower
peptidyl -prolyl isomerization of proteins and thus can allow
the relaxation of local energetically unfavorable conforma-
tional states [31]. Pin1 is known to promote conformational
changes to many proteins including cdc25 [51]. Very
recently, Pin1 homolog DoDo was found to target a
transcription factor to proteasomal degradation [29], but
the self -decline of Pin1 itself by proteasomes represents an
unprecedented event.
To summarize, our data clearly indicate a novel mecha-
nism by which phospho Bcl2 alters the destiny of cells by its
transient conformational modification. Initially, phospho Bcl2
is translocated inside the nucleus. The association of Pin1, a
nuclear peptidyl prolyl isomerase, with phospho Bcl2 induces
transient conformational change in such a way that Bcl2–
specific phosphatase loses its access. Subsequently Pin1 is
degraded by proteasomes resulting in accelerated dephos-
phorylation of phospho Bcl2 by Bcl2–specific phosphatase.
However, transient conformational change due to Pin1
Figure 8. Confocal microscopy of PC -3 cells with Bcl2 monoclonal antibody.
(A–E ) Taxol - treated. (A ) CY3 - labeled single optical section; (B ) TO-PRO
staining; (C ) merged images of (A ) and (B ); (D ) differential interference
contrast images; (E ) merged images of (A ) and (D ); ( F ) double staining of
untreated cells with CY3 and TO-PRO.
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association can lead cells to a point of no return (effector
phase) of apoptotic cascade. Apparently, dephosphorylated
Bcl2 inside the nucleus lacks antiapoptotic function and this
may be due to its inability to relocate to the mitochondria.
This explains why the cells still continue to die by apoptosis
even in the presence of the native (dephosphorylated) form
of Bcl2 (Figure 1, C and D ).
Both Bcl2 and Pin1 exert important roles in tumor cell
survival. Phosphorylation-dependent proline isomerization
catalyzed by Pin1 is essential for tumor cell survival and
entry into mitosis [54]. The combined effect of loss of
antiapoptotic function of Bcl2 and the subsequent elimination
of Pin1 might play a major role in irreversible demise of
cancer cells following Taxol treatment. In this respect, the
report on the increased affinity of phosphorylated survivin for
active Caspase-9 is quite interesting [55]. Phosphorylated
survivin can modulate the function of Caspase-9 by
stabilizing a complex between them.
Our investigation has prospective clinical significance
because Taxol is being used for treatment of several
malignancies including metastatic breast cancer [56].
Because of the overexpression of Bcl2 in cancer but not
in normal tissues, the elucidation of in -depth mechanism
of inactivation of Bcl2 by phosphorylation [9-24] will help
us to identify another molecular target for therapy.
Nonetheless, it is true that other antiapoptotic molecules
such as Bcl -xL [57] and survivin [55] are also known to
hinder resistance to therapy. At least the mechanism of
inactivation of Bcl2 can be determined to develop a
prospective therapy for a subpopulation of cancer cells
overexpressing Bcl2. The differential level of expression of
one particular protein in similar type of cancer cells is
reported in the literature. For instance, the epigenetic
inactivation of Apaf-1, a downstream proapoptotic effector
molecule is reported only in a subpopulation of metastatic
melanoma cells with functional p53 [58,59]. Thus, the
inactivating mechanism of Bcl2 by posttranslational
modification might be of paramount importance to therapy
for malignancies in which Bcl2 or Pin1overexpression [60]
plays a key role.
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